Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer

G Giaccone, P Zatloukal, J Roubec, K Floor, J Musil, M Kuta, RJ Klaveren, S Chauddhary, A Gunther, S Shamsili

Research output: Contribution to journalArticleAcademicpeer-review

212 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)4481-4486
Number of pages6
JournalJournal of Clinical Oncology
Volume27
Publication statusPublished - 2009

Research programs

  • EMC MM-04-42-02

Cite this